HealthAstraZeneca drug combination helps lung cancer patients live longer in late-stage study

AstraZeneca said its cancer drug Imfinzi, combined with Amgen’s targeted immunotherapy Imdelltra, significantly improved overall survival for patients with extensive-stage small-cell lung cancer in a late-stage trial.

AstraZenecalung cancerclinical trial

RReuters★★★☆☆2026-09-08 18:30Original